NCT05010603 · RECRUITING
Late Onset Alzheimer's Disease
This study collects blood samples and runs memory and thinking tests to look for genes that influence who gets Alzheimer's disease. It focuses on families where multiple members have been diagnosed, across African American, Hispanic, and Caucasian backgrounds. There is no assigned treatment — this is purely observational research aimed at understanding genetic risk factors. The phase is unspecified, meaning it is likely ongoing data collection rather than a drug or intervention trial.
You may qualify if
- Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases.
- a living sibling with probable or possible AD;
- a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older);
- participants in the proband's generation with an identified companion serving as an informant;
- participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent.
You're excluded if
- failure to identify an appropriate informant;
- uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder;
- discovery of additional diagnosis that could account for the clinical manifestations;
- unwillingness to participate;
- failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD);
- participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-05-16